VCM
BCRX icon

Versant Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Versant Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20K Buy
2,003
+1,521
+316% +$13.8K ﹤0.01% 1928
2026
Q1 		$4.59K Buy
482
+328
+213% +$2.55K ﹤0.01% 2406
2025
Q4 		$1.2K Hold
154
– – ﹤0.01% 2513
2025
Q3 		$1.17K Hold
154
– – ﹤0.01% 2483
2025
Q2 		$1.38K Buy
+154
New +$1.43K ﹤0.01% 2448
2023
Q3 		– Sell
-59
Closed -$415 – 1948
2023
Q2 		$415 Buy
+59
New +$473 ﹤0.01% 1873

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Versant Capital Management's BCRX Position: Q2 2026 in Review

Versant Capital Management increased its BioCryst Pharmaceuticals (BCRX) stake by 316% in Q2 2026, buying an estimated $13.8K and bringing the position to 2,003 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #1928.

Versant Capital Management first reported a position in BCRX in Q2 2023 and has held it in 6 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Versant Capital Management held 2,003 shares of BioCryst Pharmaceuticals worth $20K as of Q2 2026.
  • Versant Capital Management bought 1,521 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $13.8K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1928 holding.
  • Versant Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2023 and has held it in 6 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.